Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Advances in the Prevention, Diagnosis, and Management of Liver Diseases:...
share announcement

Advances in the Prevention, Diagnosis, and Management of Liver Diseases: 2nd Edition

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 4771

Special Issue Editors

Dr. Po-Heng Chuang

E-Mail Website
Guest Editor
1. Department of Gastroenterology, Division of Internal Medicine, Jen-Ai Hospital, Taichung 412224, Taiwan
2. Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
Interests: hepatology; liver cancer; liver tumor biopsy and ablation; contrast ultrasound
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ching-Sheng Hsu

E-Mail Website1 Website2
Guest Editor
Liver Diseases Prevention and Treatment Center, Dalin Tzu Chi Hospital, Chia-Yi and School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan
Interests: liver cancer; viral hepatitis; fatty liver; liver cirrhosis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Sheng-Nan Lu

E-Mail Website
Guest Editor
1. College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan
2. Department of Gastroenterology and Hepatology, Division of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833401, Taiwan
Interests: hepatology; liver diseases; intervention ultrasonography; epidemiology; preventive medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There are many kinds of liver diseases caused by drugs, poisons, alcohol, parasites, fungi, and viruses, metabolic or inherited, and primary liver tumors and metastatic liver cancers. We are pleased to welcome you to submit your advanced studies or new devices or drugs in the prevention, diagnosis, and management of liver parenchyma diseases, bile duct injuries, intrahepatic space-occupying lesions, and tissue or serum biomarkers.

This Special Issue welcomes your contributions covering the current aspects on the prevention, diagnosis, and management of liver diseases. Submissions may include articles pertaining to the current original research, experimental methodology, artificial intelligence, and the introduction of new devices or drugs as well as review articles, summarizing the current status of biomarkers or images or pathologic diagnosis and management of liver disease. We look forward to accepting your contributions.

Dr. Po-Heng Chuang
Prof. Dr. Ching-Sheng Hsu
Prof. Dr. Sheng-Nan Lu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver parenchyma diseases
  • fatty liver
  • hepatitis
  • intrahepaticc space-occupying lesions
  • abscess liver cancer
  • biomarkers
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2628 KiB  
Article
New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
by Ermina Stratina, Carol Stanciu, Robert Nastasa, Sebastian Zenovia, Remus Stafie, Adrian Rotaru, Tudor Cuciureanu, Cristina Muzica, Catalin Sfarti, Irina Girleanu, Horia Minea, Oana Petrea, Laura Huiban, Stefan Chiriac, Ana-Maria Singeap, Oana Vlad, Camelia Cojocariu and Anca Trifan
Diagnostics 2024, 14(14), 1475; https://doi.org/10.3390/diagnostics14141475 - 10 Jul 2024
Cited by 3 | Viewed by 2244
Abstract
Background and aims: Increases in both the prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity are closely related. Type 2 diabetes (T2DM) has been associated with metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and hepatocellular carcinoma. Semaglutide is a glucagon-like peptide-1 [...] Read more.
Background and aims: Increases in both the prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity are closely related. Type 2 diabetes (T2DM) has been associated with metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and hepatocellular carcinoma. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of T2DM and has an important role in weight loss. Also, it may represent a new therapeutic option for the treatment of MASH in obese diabetic patients. The main outcomes were changes from baseline in liver steatosis and fibrosis at week 24. Material and methods: A total of one hundred eighty-seven patients with T2DM were eligible for this prospective study; ninety-five subjects were treated with oral semaglutide, and ninety-two patients were treated with dapagliflozin as an add-on to metformin. All the subjects were evaluated using Vibration Controlled Transient Elastography (VCTE) from June to December 2022. Results: From our cohort, 54% of the patients were females, with a mean age of 59.92 ± 11.89 years and a mean body mass index (BMI) of 29.53 ± 5.33 kg/m2. Following a six-month medication period, we observed a substantial reduction in anthropometric measurements, including the BMI, waist circumference (WC), and waist-to-hip ratio (WtHr), in both groups. Regarding HbA1c, a notable decrease was observed in the semaglutide group (p < 0.001) when compared to the dapagliflozin group (p = 0.011). In addition, the liver stiffness measurement (LSM) according to VCTE improved significantly in the semaglutide group participants from 8.07 ± 2.90 kPa at baseline to 6.51 ± 3.09 kPa after medication (p < 0.001). Conclusion: The superior metabolic effects of semaglutide, correlated to dapagliflozin, may contribute to a more efficient decrease in hepatic stress and injury, leading to a substantial enhancement of liver function in T2DM patients. Further investigations conducted over an ideal timeframe are necessary to confirm the evidence presented in this study. Full article
(This article belongs to the Special Issue Advances in the Prevention, Diagnosis, and Management of Liver Diseases: 2nd Edition)
►▼ Show Figures

Figure 1

10 pages, 1358 KiB  
Article
Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis
by Nobuharu Tamaki, Kenta Takaura, Mayu Higuchi, Yutaka Yasui, Jun Itakura, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi and Masayuki Kurosaki
Diagnostics 2024, 14(13), 1317; https://doi.org/10.3390/diagnostics14131317 - 21 Jun 2024
Viewed by 1962
Abstract
Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas with a [...] Read more.
Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas with a high number of elderly people suffering from chronic liver disease has yet to be determined. Methods: This is a prospective study that included 373 consecutive patients who underwent a liver biopsy and had their ELF score measured on the same day. The diagnostic accuracy of the ELF score for liver fibrosis and the effect of age on the ELF score were investigated. Results: The median (interquartile) ELF scores in F0, F1, F2, F3, and F4 are 8.7 (8.2–9.2), 9.3 (8.8–10.0), 10.1 (9.4–10.7), 10.7 (9.9–11.2), and 12.0 (11.2–12.7), respectively. ELF scores increased with increasing liver fibrosis stage (p < 0.001). The diagnostic accuracy of the ELF score and FIB-4 for significant fibrosis (F2–4) and advanced fibrosis (F3–4) was comparable, but the ELF score had a higher diagnostic accuracy for cirrhosis (F4) than FIB-4. When patients were stratified by age of 60 years, the median ELF score did not differ by age in F2, F3, and F4. However, the median FIB-4 increased in patients with ≥60 years compared to those with <60 years in all fibrosis stages. Conclusions: ELF score has high diagnostic accuracy for liver fibrosis, regardless of age, and it could be used as a primary screening method. Full article
(This article belongs to the Special Issue Advances in the Prevention, Diagnosis, and Management of Liver Diseases: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop